Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19
Status:
Completed
Trial end date:
2021-02-22
Target enrollment:
Participant gender:
Summary
The most severe manifestations of COVID-19 include respiratory failure, coagulation problems,
and death. Inflammation and blood clotting are believed to play an important role in these
manifestations. Research in humans has shown that dipyridamole can reduce blood clotting.
This research study is being conducted to learn whether 14 days of treatment with
dipyridamole will reduce excessive blood clotting in COVID-19.
This study will enroll participants with confirmed coronavirus (SARS-CoV)-2 infection that
are admitted. Eligible participants will be randomized to receive dipyridamole or placebo for
14 days in the hospital. In addition, data will be collected from the medical record, and
there will also be blood draws during the hospitalization.